Literature DB >> 33907459

Migraine with Brainstem Aura Accompanied by Disorders of Consciousness.

Sui-Yi Xu1, Hui-Juan Li1, Jing Huang1, Xiu-Ping Li1, Chang-Xin Li1.   

Abstract

Migraine with brainstem aura (MBA) accompanied by disorders of consciousness (DOC) is a rare subtype of migraine. The pathophysiology of MBA with DOC has not been elucidated yet. Some patients have a family history of migraine, and women are more affected than men. The aura symptoms are diverse; however, when MBA is combined with DOC, the clinical manifestations are more complicated. Coma is the most common clinical manifestation. The overall duration of the patient's DOC is short and can often return to normal within half an hour. Headache often occurs after regaining consciousness and can also occur at the same time as DOC. The most common headache is located at the occipital region. Although DOC is reversible, considering the current small number of cases, we still need to improve our understanding of the disease to avoid misdiagnosis. The MBA patient's electroencephalogram and cerebral blood flow perfusion may have transient changes and may return to normal in the interictal period or after the DOC. Although triptans have traditionally been contraindicated in MBA under drug instructions, the evidence of basilar artery constriction, as postulated in MBA, is lacking. Lasmiditan is currently the first and only 5-HT 1F receptor agonist approved by the Food and Drug Administration. The calcitonin gene-related peptide receptor antagonists and monoclonal antibody therapies may be the most promising for future consideration. Here, the pathophysiology, clinical manifestations, diagnostic tools, and treatment progress for MBA with DOC are reviewed.
© 2021 Xu et al.

Entities:  

Keywords:  brainstem aura; calcitonin gene-related peptide; coma; migraine

Year:  2021        PMID: 33907459      PMCID: PMC8068516          DOI: 10.2147/JPR.S305483

Source DB:  PubMed          Journal:  J Pain Res        ISSN: 1178-7090            Impact factor:   3.133


  81 in total

Review 1.  Does inflammation have a role in migraine?

Authors:  Lars Edvinsson; Kristian Agmund Haanes; Karin Warfvinge
Journal:  Nat Rev Neurol       Date:  2019-07-01       Impact factor: 42.937

2.  Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial.

Authors:  Michel D Ferrari; Hans Christoph Diener; Xiaoping Ning; Maja Galic; Joshua M Cohen; Ronghua Yang; Matthias Mueller; Andrew H Ahn; Yael Carmeli Schwartz; Melissa Grozinski-Wolff; Lindsay Janka; Messoud Ashina
Journal:  Lancet       Date:  2019-08-16       Impact factor: 79.321

3.  Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition.

Authors: 
Journal:  Cephalalgia       Date:  2018-01       Impact factor: 6.292

4.  Effect of Ubrogepant vs Placebo on Pain and the Most Bothersome Associated Symptom in the Acute Treatment of Migraine: The ACHIEVE II Randomized Clinical Trial.

Authors:  Richard B Lipton; David W Dodick; Jessica Ailani; Kaifeng Lu; Michelle Finnegan; Armin Szegedi; Joel M Trugman
Journal:  JAMA       Date:  2019-11-19       Impact factor: 56.272

Review 5.  Novelty in Inflammation and Immunomodulation in Migraine.

Authors:  Cinzia Cavestro; Marcella Ferrero; Silvia Mandrino; Marco Di Tavi; Eugenia Rota
Journal:  Curr Pharm Des       Date:  2019       Impact factor: 3.116

6.  Getting to the Heart of the Matter: Migraine, Triptans, DHE, Ditans, CGRP Antibodies, First/Second-Generation Gepants, and Cardiovascular Risk.

Authors:  Paul G Mathew; Brad C Klein
Journal:  Headache       Date:  2019-07-18       Impact factor: 5.887

Review 7.  Calcitonin gene-related peptide in peripheral blood as a biomarker for migraine.

Authors:  César Ramón; Eva Cernuda-Morollón; Julio Pascual
Journal:  Curr Opin Neurol       Date:  2017-06       Impact factor: 5.710

Review 8.  Migraine with brainstem aura: Why not a cortical origin?

Authors:  Geneviève Demarquay; Anne Ducros; Alexandra Montavont; François Mauguiere
Journal:  Cephalalgia       Date:  2017-10-26       Impact factor: 6.292

9.  Serum apolipoprotein E may be a novel biomarker of migraine.

Authors:  Naoki Yuasa; Eiichiro Nagata; Natsuko Fujii; Masatoshi Ito; Hideo Tsukamoto; Shunya Takizawa
Journal:  PLoS One       Date:  2018-01-22       Impact factor: 3.240

10.  Time course of efficacy of ubrogepant for the acute treatment of migraine: Clinical implications.

Authors:  Peter J Goadsby; Andrew M Blumenfeld; Richard B Lipton; David W Dodick; Kavita Kalidas; Aubrey M Adams; Abhijeet Jakate; Chengcheng Liu; Armin Szegedi; Joel M Trugman
Journal:  Cephalalgia       Date:  2020-11-26       Impact factor: 6.292

View more
  1 in total

Review 1.  Role of Omics in Migraine Research and Management: A Narrative Review.

Authors:  Pragya Chaturvedi; Rahul Khan; Prachi Sahu; Abhilash Ludhiadch; Gagandeep Singh; Anjana Munshi
Journal:  Mol Neurobiol       Date:  2022-07-07       Impact factor: 5.682

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.